Skip to content

Study · In vitro (cells) · bacteria · 2005

3 results

Expression and activity of beta-defensins and LL-37 in the developing human lung.

Starner TD, Agerberth B, Gudmundsson GH, McCray PB Jr

Journal of immunology (Baltimore, Md. : 1950)1 Feb 2005Cited by 91 (Europe PMC)

PMID15661923 (opens in a new tab)DOI10.4049/jimmunol.174.3.1608 (opens in a new tab)PepBankPUB-15661923
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    Against bacteria commonly causing neonatal sepsis, each antimicrobial peptide studied, including LL‑37, showed a unique spectrum of antimicrobial activity.

    In plain wordsIn lab tests, LL‑37 and the other peptides each killed a different range of bacteria that cause infections in newborns.

    Peptide
    LL-37
    Outcome
    Not applicableSpectrum of antimicrobial activity
    Study

    bacterian: not reported in source

    Bacteria commonly causing sepsis in the neonate
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Additionally, each antimicrobial peptide exhibited a unique spectrum of antimicrobial activity and salt sensitivity against bacteria commonly causing sepsis in the neonate.
    1 context sentence
    Summary · context
    The lung is a major portal of entry for potential pathogens in the neonate, and human beta-defensins (HBDs) and LL-37 participate in pulmonary innate immunity.
  2. 02LabIn vitro (cells)Activity measurement

    Against bacteria commonly causing neonatal sepsis, each antimicrobial peptide studied, including LL‑37, showed a unique salt sensitivity of its antimicrobial activity.

    In plain wordsIn lab tests, how salt affected the germ-killing power of LL‑37 and the other peptides differed between peptides.

    Peptide
    LL-37
    Outcome
    Not applicableSalt sensitivity of antimicrobial activity
    Study

    bacterian: not reported in source

    Bacteria commonly causing sepsis in the neonate
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Additionally, each antimicrobial peptide exhibited a unique spectrum of antimicrobial activity and salt sensitivity against bacteria commonly causing sepsis in the neonate.
    1 context sentence
    Summary · context
    The lung is a major portal of entry for potential pathogens in the neonate, and human beta-defensins (HBDs) and LL-37 participate in pulmonary innate immunity.

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 03LabEndogenous levelIn vitro (cells)Other

    In human airway epithelial cultures, LL‑37 messages (mRNA) were not detected.

    In plain wordsIn lab cultures of human airway cells, the body's own LL‑37 message was not detected.

    Peptide
    LL-37
    Outcome
    Not applicableLL-37 message in airway epithelial cultures
    Study

    humann: not reported in source

    Human airway epithelial cultures
    Outcome group
    Infection and antimicrobial activity · Respiratory

    Source sentences

    Summary
    HBD-3 and LL-37 messages were not detected in airway epithelial cultures.
    1 context sentence
    Summary · context
    The lung is a major portal of entry for potential pathogens in the neonate, and human beta-defensins (HBDs) and LL-37 participate in pulmonary innate immunity.

    This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.